GSK Acquires Affinivax, Inc.

AstraZeneca Acquires Icosavax

December 12, 2023

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Icosavax, a Seattle-based clinical-stage biopharmaceutical company, in a cash tender offer valuing the deal at approximately $0.8bn upfront and up to $1.1bn including contingent payments. The acquisition brings Icosavax's virus‑like particle (VLP) platform and Phase III‑ready combination RSV/hMPV vaccine candidate IVX‑A12 into AstraZeneca's Vaccines & Immune Therapies late‑stage pipeline to strengthen respiratory vaccine capabilities for older adults and vulnerable populations.

Vaccitech plc Acquires Avidea Technologies to Expand SNAPvax Pipeline

December 13, 2021

Biotechnology

Vaccitech plc acquired US-based Avidea Technologies, Inc. for approximately $40 million (about $12.5M cash and $27.5M in Vaccitech ADS) plus potential milestone payments. The deal brings Avidea's SNAPvax™ nanoparticle platform and early-stage product candidates into Vaccitech's pipeline, expands Vaccitech's U.S. R&D presence, and adds Avidea co-founders to Vaccitech's scientific team.

GSK To Acquire RAPT Therapeutics in $2.2 Billion Deal

January 23, 2026

Biotechnology

GSK signed a definitive agreement to acquire RAPT Therapeutics for an aggregate equity value of about $2.2 billion, expanding its Respiratory, Immunology & Inflammation pipeline. The deal adds ozureprubart, a long-acting anti-IgE monoclonal antibody in Phase IIb development for prophylaxis of food-allergy reactions.

Sanofi Acquires Amunix Pharmaceuticals

December 21, 2021

Biotechnology

Sanofi has entered into an agreement to acquire Amunix Pharmaceuticals for an upfront payment of approximately $1.0 billion plus up to $225 million in potential development milestones. The acquisition gives Sanofi Amunix’s Pro‑XTEN/XPAT/XPAC masking technology and a pipeline of conditionally activated T‑cell engagers and cytokine therapies (including lead candidate AMX‑818), expanding Sanofi’s immuno‑oncology capabilities.

Pfizer Acquires Amplyx Pharmaceuticals

April 28, 2021

Biotechnology

Pfizer Inc. acquired Amplyx Pharmaceuticals, a privately held clinical-stage biotechnology company developing the antifungal candidate fosmanogepix (APX001). The deal expands Pfizer's anti-infectives pipeline and secures Amplyx's lead and early-stage assets to advance development of novel antifungal and antiviral therapies.

Avacta Increases Equity Stake in AffyXell Therapeutics after Milestone

April 13, 2022

Biotechnology

Avacta Group plc has increased its equity stake in AffyXell Therapeutics to 22% after triggering a milestone by transferring Affimer-related IP into the joint venture. AffyXell — a joint venture between Avacta and Daewoong Pharmaceutical in South Korea — combines Avacta's Affimer platform with Daewoong's mesenchymal stem cell (MSC) platform to develop next-generation cell therapies.